PDCD1 and cancer: Monoclonal antibodies are used to target immune checkpoint molecules by inhibiting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1), together results in a shift mode of treatment of malignant tumors (22).